Drug Profile

Fludrocortisone acetate - Eye Co

Latest Information Update: 28 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eye Co
Class Antihypotensives; Corticosteroids; Eye disorder therapies
Mechanism of Action Glucocorticoid receptor agonists; Mineralocorticoid receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Dry age-related macular degeneration

Most Recent Events

28 Dec 2023 No recent reports of development identified for phase-I development in Dry age-related macular degeneration in Australia (Intravitreous, Injection)
07 Dec 2021 311237 CTP push- KDM updated, HE added
24 Sep 2021 Eye Co completes a phase I trial in Dry age-related macular degeneration in Australia (Intavitreous, Injection) in September 2021 (ACTRN12618001308280)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com